Event Participants
Executives
3 Alpesh Dalal, Keshav Bhutada, Monish Shah
Analysts
17 Ajay, Akhilesh Pathak, Amish Kanani, Anubhav Goel, Deepak Sharma, Gaurav Bhardwaj, Krisha Kansara, Nidhi Kumari, Nikhil Upadhyay, Nishant, Rakesh Mehta, Sajal Kapoor, Sumit Gupta, Surendra Khemka, Thirumala Reddy, Tushar Bohra, Yash Doshi
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue | ₹469 crores | +43% YoY; highest-ever quarterly revenue, fourth consecutive record quarter |
| API Revenue | ₹260 crores | +15% YoY; driven by improved offtake from expanded capacities and strong captive demand |
| Formulation Revenue | ₹198 crores | +100%+ YoY; ex-licensing base business +112%, led by complex FDA portfolio in US |
| Biologics Revenue | ₹52 crores | +42% YoY; driven by licensing/partnership and CDMO deal momentum |
| Gross Margin | 71% | Slight dip from raw material inflation; complex product mix supports high margins |
| EBITDA | ₹139 crores | +42% YoY; margin 30%, consistent with ~30% range maintained over recent quarters |
| Operating PBT | ₹92 crores | Vs ₹50 crores in Q1 FY26; before JV share and exceptional items |
| Reported PBT | ₹98 crores | +98% YoY |
| PAT | ₹101 crores | +115% YoY; aided by negative tax rate from deferred tax liability reversal |
| Normalized Tax Rate | ~25% expected | Post new regime adoption; effective rate lower with MAT credit utilization |
| ROCE | 12.5% blended; 18.3% ex-biologics | Up from 8.8% in FY25; adjusted for early-stage businesses |
| Net Debt/EBITDA | 1.3x | Down from 6.7x three years ago |
| Capex | ₹114 crores | Q1 spend, funded via internal accruals; peptide capacity commissioning by FY27-end |
| Credit Rating | AA- | Upgraded from A+ |
Geographic & Segment Commentary
API: ₹260 crores revenue, +15% YoY. Growth driven by improved offtake of key products from newly expanded capacities and strong captive demand from FTF finished formulation vertical. Specialty CDMO within API saw strong traction from new client acquisitions in developed markets. Focus remains on CDMO, Peptides, and Oncology, with three NCE advanced programs set to commercialize in FY28 and 15 new oncology product validations targeted for FY27.
Formulation: ₹198 crores revenue, more than doubled YoY with ex-licensing base business growing ~112%. Complex FDA portfolio in US led the growth, supported by EU and ROW regions. NorUDCA, the first NCE approved in India, is performing as expected with strong FY27 order visibility; global Phase 2 studies start in FY27. Three 505(b)(2) products approved last year continue growing QoQ, while Rotigotine transdermal patch, Abrexin, Enzalutamide, and Abridron are on track for FY28 launches.
Biologics: ₹52 crores revenue, +42% YoY, driven by licensing/partnership and CDMO momentum. Aflibercept clinical studies completed, with India launch on track for FY27 through three ophthalmic partners. Nivolumab partnered with Orion Corporation for Europe; India launch expected FY28. Over five biosimilars in pipeline; CDMO business has 6+ active NCE programs with one entering human studies in FY27. Recombinant human albumin Phase 1 complete, global Phase 3 starting; first ADC biosimilar entering human studies in FY27.
Company-Specific & Strategic Commentary
Transformation Scorecard: Net debt/EBITDA improved from 6.7x to 1.3x in three years, ROCE now double-digit, credit rating upgraded to AA-, and portfolio shifted from API ingredients to first-in-class drugs and complex molecule manufacturing. Management stated "reinvesting is largely behind us, harvesting is ahead of us."
Integration Advantage: Shilpa positioned as one-stop solution - API integrated with formulation, biologics from clone to fill-finish, complete albumin chain. This integrated capability is a key differentiator for winning CDMO customers seeking consolidated solutions.
CDMO Strategy: 25+ NCE programs across API division with three late-stage programs commercializing FY28; 20+ CDMO customers. Strategic equity investments in partners like mAbTree and Alveolus Bio provide profit-share upside beyond supply contracts; selective criteria based on therapy and corporate strategy fit.
Peptide Capacity Expansion: Large CapEx investment in peptide manufacturing in India, enabling end-to-end solid phase synthesis, with commissioning by end FY27.
NorUDCA Global Expansion: European and US scientific advice completed; global Phase 2 clinical studies commencing FY27. Differentiated mechanism directly targeting liver enzymes vs GLP-1s like Semaglutide for fatty liver indications.
Biologics Partnering Model: First European biosimilar partnership (Nivolumab with Orion); three partnerships for Aflibercept in Indian ophthalmic market. Mixed strategy - biosimilars and CDMO for short/mid-term, strategic partnerships for long-term.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| EBITDA Margin | ~30% range | CFO: "We would put margins to remain in similar range"; conservative stance to over-deliver |
| Tax Rate | ~25% normalized | After switching to new tax regime; effective rate lower with MAT credit utilization |
| Growth Trajectory | Robust, no numeric guidance | Management declined to provide specific numbers; expects faster profitability growth driving higher ROCE |
| Formulation Revenue | Strong growth possibility | Existing and new pipeline launches; NorUDCA strong order visibility for FY27 |
| Biologics Revenue | Significantly higher growth | Smaller base; industry shift toward biologics; more partnerships expected |
| ROCE | Higher in coming year | Improved business mix and operating leverage; adjusted ROCE already 18.3% |
| API Revenue | Steady growth in FY27 | Focus on CDMO, peptides, oncology; 15 new oncology validations expected |
Risks & Constraints
| Risk | Context |
|---|---|
| Regulatory challenges | Unexpected regulatory issues could slow growth trajectory (CFO flagged). Company maintains robust compliance, but regulatory authority perspectives can vary. |
| Raw material inflation | Global political situation driving up raw material prices, slightly pressuring gross margins; only partially passable to customers. |
| US tariff policy | Potential tariffs on Indian pharma exports; company's complex/differentiated US portfolio minimizes immediate impact, but evaluating US manufacturing as hedge pending policy clarity. |
| Product development failures | Not all programs succeed; failures budgeted and hit P&L directly. Uncertainties in clinical outcomes and timelines across 25+ NCE programs. |
| Partner dependence | Reliance on partners for commercial milestones - Unicycive received CRL from USFDA with refile expected Q3; global Phase 2 for NorUDCA depends on successful execution. |
Q&A Highlights
Capital Allocation & Capex Strategy
- Question: With investments monetizing, what would make you say you have enough capability and prioritize sorting existing assets over building new? (Sajal Kapoor)
- Answer: Historical CapEx in biologics and formulations has low utilization - room for capacity utilization growth; API has high utilization where additional CapEx continues. Mix gives confidence enough capital is deployed for upcoming growth. (Keshav Bhutada)
- Question: Are we getting a sense that one plus one is greater than two now? (Sajal Kapoor)
- Answer: Shilpa is built on integration - API integrated with formulation, biologics clone to fill-finish, albumin end-to-end. Industry needs one-stop solution capabilities. (Keshav Bhutada)
CDMO Growth & Strategic Investments
- Question: Is specialty CDMO the next leg of growth for API? How many projects will start commercial phase in FY27-28? (Nikhil Upadhyay)
- Answer: Yes, specialty CDMO will be a leading driver; three late-stage programs entering commercialization next year. Program count details not disclosed. (Keshav Bhutada)
- Question: What is the strategy of taking stakes in companies to provide CDMO services? (Anubhav Goel)
- Answer: Unique confidential strategy; highly selective - must fit therapy and corporate strategy. Will disclose more if deal sizes increase in future. (Keshav Bhutada)
NorUDCA Performance & Competitive Positioning
- Question: How much of domestic formulation revenue came from NorUDCA? What about six-month curability data? Does Semaglutide's fatty liver approval impact us? (Krisha Kansara)
- Answer: Product-level sales not disclosed; strong order trajectory gives confidence. Clinical data published online; Phase 4 study ongoing. NorUDCA directly attacks liver enzymes - different mechanism than Semaglutide for liver fibrosis. (Keshav Bhutada)
Margin Trajectory & Sustainability
- Question: How sustainable is the ~29-30% EBITDA margin? (Rakesh Mehta)
- Answer: Consistently maintaining ~30% levels; being conservative and expecting similar range going forward. (Alpesh Dalal)
- Question: What's driving gross margin, and what would it be excluding one-offs? (Sumit Gupta)
- Answer: Complex products like Rotigotine, Abraxane, NorUDCA drive margins. Raw material price increases from global political situation caused slight dip; partially passed on to customers - quantifying the impact is difficult. (Keshav Bhutada, Alpesh Dalal)
Tax Regime Shift
- Question: Why move to new tax regime when you could claim 100% R&D deduction on capital goods? (Nishant)
- Answer: R&D units already fully functional with no significant R&D CapEx coming; lose accumulated MAT credit if not switching. Tax rate differential ~9.75%, plus MAT credit utilization at 25% of tax brings effective rate down ~6-6.5%. (Alpesh Dalal)
US Tariff Exposure
- Question: How will you counter US tariffs given ₹45 crores exports? (Nishant)
- Answer: Products are complex and differentiated, not commodity generics - minimal impact. Evaluating US manufacturing facility but waiting for policy clarity from the current administration. (Keshav Bhutada)
Licensing Business Model
- Question: What are the economics of license and service income? Is it recurring or one-time? (Ajay)
- Answer: Licensing income comes after development spends in earlier periods; received amounts are significantly higher than program spends but not every program succeeds - failures hit P&L. Model is portfolio development and licensing; CDMO is a separate business. (Alpesh Dalal)
Biologics Strategy & Scale-up
- Question: How will you scale biologics from ₹150 crores to ₹300-400 crores? (Krisha Kansara)
- Answer: Strong team with wide experience plus consultants with US/EU regulatory understanding; further details to be shared offline. (Keshav Bhutada)
- Question: What's the growth trajectory for biologics? (Rakesh Mehta)
- Answer: Significantly higher growth on smaller base; industry moving toward biologics provides additional opportunity. No specific numbers provided. (Alpesh Dalal)
Key Takeaway
Shilpa Medicare delivered a record Q1 FY27 with revenue of ₹469 crores (+43% YoY), EBITDA of ₹139 crores (+42%, 30% margin), and PAT of ₹101 crores (+115%), supported by gross margins of 71%. Formulation led the growth, more than doubling YoY (ex-licensing +112%) on complex FDA products, while API rose 15% and Biologics 42%. The company leveraged its integrated API-to-formulation and clone-to-fill-finish capabilities, with three late-stage NCE programs set to commercialize in FY28 and NorUDCA gaining momentum in India while entering global Phase 2. ROCE improved to 12.5% (18.3% ex-biologics) and credit rating was upgraded to AA-, while net debt/EBITDA fell to 1.3x. Management maintained a disciplined stance, declining numeric guidance but signaling sustained ~30% EBITDA margins and higher returns as biologics, CDMO, and albumin assets monetize. Key watch-points include regulatory hurdles, raw material inflation, US tariff policy, and successful global clinical progression of biosimilars and NorUDCA.